Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB – Research Report) and Immatics (IMTX – Research Report).
Biogen (BIIB)
Bank of America Securities analyst Geoff Meacham reiterated a Hold rating on Biogen yesterday and set a price target of $290.00. The company’s shares closed last Wednesday at $231.69.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Biogen with a $330.00 average price target, representing a 34.3% upside. In a report issued on October 26, Wedbush also maintained a Hold rating on the stock with a $266.00 price target.
See today’s best-performing stocks on TipRanks >>
Immatics (IMTX)
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Immatics yesterday and set a price target of $16.00. The company’s shares closed last Wednesday at $9.56.
According to TipRanks.com, Stranahan is a 4-star analyst with an average return of
Immatics has an analyst consensus of Strong Buy, with a price target consensus of $18.75, implying an 86.4% upside from current levels. In a report issued on November 2, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BIIB:
